(61 days)
The Trinity Biotech Captia ENA Profile Enzyme-Linked Immunosorbent Assays (ELISA) is intended for the detection of antibodies to individually coated Smith, Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 and Jo-1 in a single serum specimen. The results of the assay are to be used as an aid in the diagnosis of Systemic Lupus Erythematosis (SLE), scleroderma, Sjogren's syndrome (SS), or other systemic rheumatic diseases.
Not Found
This document is a 510(k) clearance letter from the FDA for a diagnostic device, not a study report. As such, it does not contain the detailed information required to describe acceptance criteria and a study proving device performance in the way a scientific publication or a full regulatory submission would.
Therefore, I cannot extract the requested information. The document focuses on regulatory approval, stating that the device is "substantially equivalent" to a legally marketed predicate device, rather than providing a detailed breakdown of a clinical study demonstrating its performance against specific acceptance criteria.
§ 866.5100 Antinuclear antibody immunological test system.
(a)
Identification. An antinuclear antibody immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the autoimmune antibodies in serum, other body fluids, and tissues that react with cellular nuclear constituents (molecules present in the nucleus of a cell, such as ribonucleic acid, deoxyribonucleic acid, or nuclear proteins). The measurements aid in the diagnosis of systemic lupus erythematosus (a multisystem autoimmune disease in which antibodies attack the victim's own tissues), hepatitis (a liver disease), rheumatoid arthritis, Sjögren's syndrome (arthritis with inflammation of the eye, eyelid, and salivary glands), and systemic sclerosis (chronic hardening and shrinking of many body tissues).(b)
Classification. Class II (performance standards).